SLXN
NASDAQSilexion Therapeutics Corp
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$0.16-2.42 (-93.87%)
2026-07-162026-10-16
News · 26 weeks73+200%
2026-04-192026-10-11
Mix3990d
- SEC Filings26(67%)
- Other9(23%)
- Leadership2(5%)
- Offering2(5%)
Latest news
25 items- SECSEC Form DEF 14A filed by Silexion Therapeutics CorpDEF 14A - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- PRSilexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic CancerGlobal Phase 2/3 trial evaluates SIL204 in combination with standard chemotherapy in patients with locally advanced pancreatic cancer Integrated regimen combines direct EUS-guided intratumoral delivery to penetrate tumor stroma with subcutaneous dosing; first patient treated at Tel Aviv Sourasky Medical Center (Ichilov) Grand Cayman, Cayman Islands and Ramat Gan, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that the first patient worldwide has been successfully dosed in its Phase 2/3 clinical t
- SECSEC Form 424B3 filed by Silexion Therapeutics Corp424B3 - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- PRSilexion Therapeutics Announces Exercise of WarrantsCayman Islands, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding series E warrants to purchase up to an aggregate of 3,216,928 of the Company’s ordinary shares originally issued in August 2026 having a reduced exercise price of $0.2603 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-298137). The gross proceeds to
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Silexion Therapeutics CorpSCHEDULE 13D/A - Silexion Therapeutics Corp (0002022416) (Subject)
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- PRSilexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven CancersTranslational research demonstrates that SIL204 utilizes native serum lipids to facilitate intracellular delivery and robust KRAS oncogene knockdown Findings validate that physiological lipoprotein levels are sufficient for cellular entry without requiring artificial nanoparticles, supporting systemic administration in the Company's Phase 2/3 clinical program Grand Cayman, Cayman Islands, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced positive new findings from an ongoing translational study evaluating t
- SECSEC Form PRE 14A filed by Silexion Therapeutics CorpPRE 14A - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSEC Form DEFA14A filed by Silexion Therapeutics CorpDEFA14A - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSEC Form DEFA14A filed by Silexion Therapeutics CorpDEFA14A - Silexion Therapeutics Corp (0002022416) (Filer)
- PRSilexion Therapeutics to Participate in September 2026 Industry and Investor ConferencesGrand Cayman, Cayman Islands, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that members of its management team will participate in the following industry and investor conferences in September 2026: Oncology & Immunology Innovation Partnering & Licensing SummitPresentation date: September 9, 2026Location: Hotel Commonwealth, Boston, MAFormat: PresentationPresenter: Dr. Mitchell Shirvan, Chief Scientific and Development Officer 8th Annual RAS-Targeted Drug Development SummitPresentation date: September 10
- SECSEC Form DEF 14A filed by Silexion Therapeutics CorpDEF 14A - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Silexion Therapeutics CorpSCHEDULE 13D/A - Silexion Therapeutics Corp (0002022416) (Subject)
- SECSEC Form SCHEDULE 13G filed by Silexion Therapeutics CorpSCHEDULE 13G - Silexion Therapeutics Corp (0002022416) (Subject)
- SECSEC Form PRE 14A filed by Silexion Therapeutics CorpPRE 14A - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSEC Form 10-Q filed by Silexion Therapeutics Corp10-Q - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- PRSilexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateSuccessfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel Aviv Sourasky Medical Center in July 2026 following clinical trial authorizations from regulators in both Israel and Germany Expanded the therapeutic profile of SIL204 with new preclinical immuno-oncology data supporting a coordinated immune-sensitization signature across three key immune pathways and four KRAS mutations, reinforcing the rationale for future combination with anti-PD-(L)1 checkpoint inhibitor therapies Advanced operational and financial readiness for the Phase 2/3 program, including initiation of GMP clini
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Silexion Therapeutics Corp (0002022416) (Filer)
SLXN FAQ
4 questionsWhere does SLXN stock trade?
Silexion Therapeutics Corp (SLXN) is listed on NASDAQ.What sector and industry is SLXN in?
Silexion Therapeutics Corp operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What companies are similar to SLXN?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare SLXN side-by-side with any of them on Quantisnow.How can I track SLXN on Quantisnow?
Quantisnow aggregates Silexion Therapeutics Corp's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SLXN to receive live email and push alerts on every new disclosure.